Sanofi-Aventis (France), Micromet Seal Early-Stage Cancer Drug Deal; Micromet Could Get Up to $475 Million

Reuters -- Sanofi-Aventis (SASY.PA) and U.S. biotech Micromet (MITI.O) signed a global deal to develop an early-stage cancer treatment, with the French drugmaker paying Micromet as much as 320 million euros ($475 million) if milestones are met.